Hypertensive Disorders in Pregnancy and Mortality at Delivery Hospitalization — United States, 2017–2019

Abstract

Hypertensive disorders in pregnancy (HDPs), defined as prepregnancy (chronic) or pregnancy-associated hypertension, are common pregnancy complications in the United States.* HDPs are strongly associated with severe maternal complications, such as heart attack and stroke ( 1 ), and are a leading cause of pregnancy-related death in the United States. † CDC analyzed nationally representative data from the National Inpatient Sample to calculate the annual prevalence of HDP among delivery hospitalizations and by maternal characteristics, and the percentage of in-hospital deaths with an HDP diagnosis code documented. During 2017–2019, the prevalence of HDP among delivery hospitalizations increased from 13.3% to 15.9%. The prevalence of pregnancy-associated hypertension increased from 10.8% in 2017 to 13.0% in 2019, while the prevalence of chronic hypertension increased from 2.0% to 2.3%. Prevalence of HDP was highest among delivery hospitalizations of non-Hispanic Black or African American (Black) women, non-Hispanic American Indian and Alaska Native (AI/AN) women, and women aged ≥35 years, residing in zip codes in the lowest median household income quartile, or delivering in hospitals in the South or the Midwest Census regions. Among deaths that occurred during delivery hospitalization, 31.6% had any HDP documented. Clinical guidance for reducing complications from HDP focuses on prompt identification and preventing progression to severe maternal complications through timely treatment ( 1 ). Recommendations for identifying and monitoring pregnant persons with hypertension include measuring blood pressure throughout pregnancy, § including self-monitoring. Severe complications and mortality from HDP are preventable with equitable implementation of strategies to identify and monitor persons with HDP ( 1 ) and quality improvement initiatives to improve prompt treatment and increase awareness of urgent maternal warning signs ( 2 ). Delivery hospitalization data for 2017–2019 were analyzed from the National Inpatient Sample, a nationally representative sample of all U.S. hospital discharges. ¶ CDC identified delivery hospitalizations among females aged 12–55 years using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis and procedure codes pertaining to delivery and diagnosis-related group delivery codes.** HDPs were categorized using ICD-10-CM diagnosis codes †† for chronic hypertension, §§ pregnancy-associated hypertension, ¶¶ and unspecified maternal hypertension. Deaths were identified based on patient hospital discharge disposition. Weighted annual prevalence (percentage) and 95% CI for HDP overall and by each type were calculated. Change in annual prevalence of HDP overall and by type was assessed using a linear trend test. Pooling data from this period, CDC calculated the weighted prevalence and 95% CIs for HDP by selected maternal characteristics (i.e., age group, race and ethnicity, and primary payer at delivery hospitalization) and characteristics of the community in which they lived (i.e., county-level rural-urban classification, zip code–level median household income, and hospital region).*** Rao-Scott chi-square tests of independence were used to assess whether HDP prevalence differed by characteristics. Percentage of deaths during delivery hospitalization with a documented HDP diagnosis code were calculated. All analyses were conducted using SAS software (version 9.4; SAS Institute); SAS survey procedures and weighting were used to account for complex sampling in the National Inpatient Sample. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy. ††† During 2017–2019, the prevalence of HDP among delivery hospitalizations increased from 13.3% to 15.9% (Figure 1), an increase of approximately 1 percentage point annually. Linear trend tests suggested that change in annual prevalence of HDP overall, pregnancy-associated hypertension, and chronic hypertension increased during 2017–2019, while prevalence of unspecified maternal hypertension remained stable. The prevalence of pregnancy-associated hypertension increased from 10.8% to 13.0% and that of chronic hypertension increased from 2.0% to 2.3%. FIGURE 1 Prevalence of hypertensive disorders in pregnancy* among delivery hospitalizations, by year — National Inpatient Sample, United States, 2017–2019 Abbreviations: HDP = hypertensive disorder in pregnancy; HTN = hypertension; PAH = pregnancy-associated hypertension. * HDPs are defined as chronic hypertension, pregnancy-associated hypertension (i.e., gestational hypertension, preeclampsia, eclampsia, and chronic hypertension with superimposed preeclampsia), and unspecified maternal hypertension. This figure is a line chart showing the prevalence of hypertensive disorders in pregnancy among delivery hospitalizations, by year, in the United States during 2017–2019 according to the National Inpatient Sample. During 2017–2019 combined, prevalence of HDP overall was 14.6%. Prevalence varied overall and by HDP type for all maternal characteristics evaluated in the study (Table). Prevalence of any HDP was higher among delivery hospitalizations to women aged 35–44 (18.0%) and 45–55 years (31.0%) than to younger women, to Black (20.9%) and AI/AN (16.4%) women than to women of other racial and ethnic groups, to those residing in rural counties (15.5%) and in zip codes in the lowest median household-level income quartile (16.4%) than those residing in metropolitan or micropolitan counties or in zip codes in higher household-level income quartiles, or delivering in hospitals in the South (15.9%) or Midwest (15.0%) U.S. Census regions than in other Census regions. These differences in HDP prevalence were similar across HDP types. TABLE Prevalence of hypertensive disorders in pregnancy, by patient-, hospital- and zip code–level characteristics — National Inpatient Sample, United States, 2017–2019 Characteristic Any hypertensive disorder in pregnancy* Chronic hypertension Pregnancy-associated hypertension Unspecified maternal hypertension No.† Row % (95% CI) No. Row % (95% CI) No. Row % (95% CI) No. Row % (95% CI) Total no. of cases 319,913 — 47,218 — 259,458 — 13,237 — Maternal age group, yrs 12–24 73,421 13.9 (13.7–14.1) 5,593 1.1 (1.0–1.1) 65,378 12.4 (12.2–12.5) 2,450 0.5 (0.4–0.5) 25–29 85,358 13.5 (13.3–13.7) 10,984 1.7 (1.7–1.8) 71,010 11.2 (11.1–11.4) 3,364 0.5 (0.5–0.6) 30–34 89,242 14.3 (14.1–14.4) 14,982 2.4 (2.3–2.4) 70,287 11.2 (11.1–11.4) 3,973 0.6 (0.6–0.7) 35–44 70,395 18.0 (17.7–18.2) 15,341 3.9 (3.8–4.0) 51,672 13.2 (13.0–13.4) 3,382 0.9 (0.8–0.9) 45–55 1,497 31.0 (29.7–32.4) 318 6.6 (5.9–7.3) 1,111 23.0 (21.8–24.2) 68 1.4 (1.1–1.7) Race and ethnicity § Asian or Pacific Islander 12,183 9.3 (8.8–9.7) 1,616 1.2 (1.1–1.3) 10,134 7.7 (7.3–8.1) 433 0.3 (0.3–0.4) Black 66,316 20.9 (20.5–21.2) 13,639 4.3 (4.2–4.4) 49,568 15.6 (15.3–15.9) 3,109 1.0 (0.9–1.0) Hispanic 54,702 12.5 (12.2–12.8) 6,561 1.5 (1.5–1.5) 46,148 10.6 (10.3–10.8) 1,993 0.5 (0.4–0.5) American Indian and Alaska Native 2,525 16.4 (15.4–17.5) 318 2.1 (1.8–2.3) 2,103 13.7 (12.7–14.6) 104 0.7 (0.5–0.8) Another race 11,659 12.0 (11.6–12.3) 1,400 1.4 (1.4–1.5) 9,781 10.1 (9.7–10.4) 478 0.5 (0.4–0.5) White 162,122 14.7 (14.5–14.9) 22,358 2.0 (2.0–2.1) 133,052 12.1 (11.9–12.2) 6,712 0.6 (0.6–0.6) Missing 10,406 12.7 (12.2–13.1) 1,326 1.6 (1.5–1.7) 8,672 10.6 (10.2–11.0) 408 0.5 (0.4–0.6) Payer Public¶ 139,227 14.8 (14.6–15.0) 21,541 2.3 (2.2–2.3) 111,543 11.8 (11.7–12.0) 6,143 0.7 (0.6–0.7) Private insurance 166,455 14.8 (14.7–15.0) 23,826 2.1 (2.1–2.2) 136,153 12.1 (12.0–12.3) 6,476 0.6 (0.6–0.6) Self-pay/Other 13,837 11.9 (11.6–12.2) 1,791 1.5 (1.5–1.6) 11,443 9.8 (9.5–10.1) 603 0.5 (0.5–0.6) Rurality (county-level) Metropolitan 275,342 14.6 (14.4–14.8) 40,136 2.1 (2.1–2.2) 224,232 11.9 (11.7–12.0) 10,974 0.6 (0.6–0.6) Micropolitan 25,844 14.8 (14.5–15.0) 4,026 2.3 (2.2–2.4) 20,497 11.7 (11.5–11.9) 1,321 0.8 (0.7–0.8) Rural** 18,139 15.5 (15.1–15.8) 2,980 2.5 (2.4–2.7) 14,241 12.1 (11.9–12.4) 918 0.8 (0.7–0.8) Median household-level income national quartile for patient zip code †† Q1 98,661 16.4 (16.1–16.6) 16,218 2.7 (2.6–2.8) 78,022 12.9 (12.7–13.2) 4,421 0.7 (0.7–0.8) Q2 81,089 14.7 (14.5–14.9) 11,916 2.2 (2.1–2.2) 65,747 11.9 (11.8–12.1) 3,426 0.6 (0.6–0.6) Q3 77,387 14.4 (14.3–14.6) 10,829 2.0 (2.0–2.1) 63,629 11.9 (11.7–12.0) 2,929 0.5 (0.5–0.6) Q4 60,014 12.7 (12.5–12.9) 7,830 1.7 (1.6–1.7) 49,857 10.5 (10.3–10.7) 2,327 0.5 (0.5–0.5) Hospital region §§ Northeast 48,527 13.9 (13.5–14.4) 6,746 1.9 (1.8–2.0) 40,017 11.5 (11.1–11.9) 1,764 0.5 (0.5–0.5) Midwest 69,181 15.0 (14.7–15.3) 9,736 2.1 (2.0–2.2) 56,611 12.3 (12.0–12.5) 2,834 0.6 (0.6–0.6) South 136,435 15.9 (15.7–16.2) 22,355 2.6 (2.5–2.7) 107,940 12.6 (12.4–12.8) 6,140 0.7 (0.7–0.7) West 65,770 12.7 (12.4–13.0) 8,381 1.6 (1.6–1.7) 54,890 10.6 (10.4–10.9) 2,499 0.5 (0.5–0.5) 
Abbreviation: Q = quartile. * Any hypertensive disorder in pregnancy includes chronic hypertension, pregnancy-associated hypertension, and unspecified maternal hypertension. † Numbers are unweighted. § Patients with Hispanic ethnicity are classified as Hispanic and all non-Hispanic patients are classified according to their reported race. The Healthcare Cost and Utilization Project (HCUP) race and ethnicity category Native American is expressed as American Indian and Alaska Native. ¶ Public insurance includes Medicare and Medicaid. ** Rural defined as nonmetropolitan and nonmicropolitan counties. †† 2017 (Q1 = $1–$43,999, Q2 = $44,000–$55,999, Q3 = $56,000–73,999, Q4 = ≥$74,000); 2018 (Q1 = $1–$45,999, Q2 = $46,000–$58,999, Q3 = $59,000–$78,999, Q4 = ≥$79,000); 2019: Q1 = $1–$47,999, Q2 = $48,000–$60,999, Q3 = $61,000–$81,999, Q4 = ≥$82,000. §§ Hospital region is the census region as defined by the U.S. Census Bureau. Among maternal deaths that occurred during delivery hospitalization, 31.6% had any HDP documented and 24.3% had pregnancy-associated hypertension documented. Chronic or unspecified maternal hypertension was documented in 7.4% of deaths §§§ (Figure 2). FIGURE 2 Proportion of deaths* occurring during delivery hospitalization with a documented diagnosis code of a hypertensive disorder in pregnancy † — National Inpatient Sample, United States, 2017–2019 Abbreviation: HDP = hypertensive disorder in pregnancy. * This study did not assign cause of death but instead examined the proportion of in-hospital deaths with an HDP diagnosis code documented among delivery hospitalizations. † HDPs are defined as chronic hypertension, pregnancy-associated hypertension (i.e., gestational hypertension, preeclampsia, eclampsia, and chronic hypertension with superimposed preeclampsia), and unspecified maternal hypertension. Proportions for chronic and unspecified maternal hypertension are combined to conform to the Agency for Healthcare Research and Quality’s data use agreement, which prohibits reporting estimates based on fewer than 11 unweighted observations. This figure is a bar chart showing the proportion of deaths occurring during delivery hospitalization with a documented diagnosis code of a hypertensive disorder in pregnancy in the United States during 2017–2019— according to the National Inpatient Sample. Discussion During 2017–2019, HDPs affected approximately one in seven delivery hospitalizations; prevalence increases were largely driven by increases in pregnancy-associated hypertension. HDPs were documented in approximately one in five delivery hospitalizations among Black women and one in three among women aged 45–55 years. An HDP diagnosis code was documented in approximately one in three deaths occurring during delivery hospitalization. Timely diagnosis and treatment of HDP are critical to preventing severe complications and mortality ( 1 ). Prevalence of risk factors for HDP, such as advanced maternal age, obesity, and diabetes mellitus, have increased in the United States ( 1 ), and might explain the increase in HDP prevalence. Women with a history of pregnancy-associated hypertension are at increased risk for cardiovascular disease compared with women with normotensive pregnancies. ¶¶¶ Addressing risk factors for HDP across the lifespan is important for preventing HDP and improving future health.**** There are substantial racial and ethnic disparities in HDP prevalence. Compared with non-Hispanic White women, non-Hispanic Black women have higher odds of entering pregnancy with chronic hypertension and developing severe preeclampsia ( 3 ). Factors that contribute to racial and ethnic inequities in chronic and pregnancy-induced hypertension include higher prevalences of HDP risk factors ( 4 ), as well as differences in access to health care and the quality of health care delivered ( 5 ). Racial bias within the U.S. health care system can affect HDP care from screening and diagnosis to treatment ( 6 ). Furthermore, psychosocial stress from experiencing racism is associated with chronic hypertension ( 7 ). In a study of racial and ethnic disparities in pregnancy-related deaths, those caused by HDP among Black and AI/AN women were found to be substantially higher than those among White women ( 8 ), highlighting the importance of addressing HDP to reduce inequities in pregnancy-related mortality. Regional and rural-urban differences in HDP prevalence have been previously reported ( 9 ). Place-based disparities in HDP prevalence might be due to differences in prevalence of HDP risk factors, including diet, tobacco use, physical activity patterns, poverty, or access to care. †††† Rural counties are at higher risk for pregnancy-related mortality than metropolitan counties ( 10 ). A strategy to address place-based disparities in HDP and pregnancy-related mortality can include strengthening regional networks of health care facilities providing risk-appropriate maternal care through telemedicine and transferring delivery care of persons with high-risk conditions to facilities that can provide specialty services. §§§§ Clinical guidance for reducing complications from HDP focuses on prompt identification and preventing progression to severe maternal complications. Recommendations for identifying and monitoring pregnant persons with hypertension include measuring blood pressure throughout pregnancy, including self-monitoring. ¶¶¶¶ Recommendations for preventing preeclampsia include low-dose aspirin for persons at risk and exercise programs.***** Once a diagnosis of an HDP is received, management strategies include blood pressure–lowering medication, ††††† prevention of eclamptic seizures (e.g., administration of magnesium sulfate), and close maternal and fetal monitoring and coordination and continuity of care during the postpartum period. §§§§§ At the systems level, perinatal quality collaboratives (PQCs) ¶¶¶¶¶ implement evidence-based quality improvement initiatives in health care facilities, including those to address severe hypertension.****** PQCs use collaborative learning, training, toolkits, and maternal safety bundles (e.g., Alliance for Innovation on Maternal Health Patient Safety Bundles †††††† ) to improve the quality of care and outcomes statewide. Maternal mortality review committees (MMRCs) provide recommendations for preventing future pregnancy-related deaths, including those attributable to HDP, and often collaborate with PQCs to translate MMRC recommendations into clinical and health systems interventions. Health communication campaigns increase awareness of urgent warning signs of HDP that indicate need for immediate care.§§§§§§ Strategies to address health inequities in HDP include addressing implicit, institutional, and structural racism, disparate access to clinical care, social determinants of health, and engagement of community partners ( 2 ). The findings in this report are subject to at least four limitations. First, identification of delivery hospitalizations and HDP is dependent upon accurate ICD-10-CM coding. Less severe cases of HDP might not be coded. In this study, approximately 4% of HDP was documented as unspecified maternal hypertension, which precludes accurate documentation of HDP type. Second, deaths identified using discharge disposition might underestimate deaths during delivery hospitalization.¶¶¶¶¶¶ These data do not represent the universe of pregnancy-related deaths, such as those that occur preceding or after delivery hospitalizations.******* This study did not assign cause of death but instead examined the proportion of in-hospital deaths occurring during delivery hospitalization with an HDP diagnosis code documented. Third, CDC was unable to identify persons who delivered more than once during the study period; the unit of analysis is delivery hospitalization. Finally, small sample sizes did not permit the disaggregation of deaths attributable to less frequent types of HDP and other maternal characteristics. The prevalence of HDP increased during the 3-year study period with noted racial and ethnic, sociodemographic, and place-based disparities. Severe HDP-associated maternal complications and mortality are preventable with equitable implementation of public health and clinical strategies. These include efforts across the life course for preventing HDP, identifying, monitoring, and appropriately treating those with HDP with continuous and coordinated care, increasing awareness of urgent maternal warning signs, and implementing quality improvement initiatives to address severe hypertension. Summary What is already known about this topic? Hypertensive disorders in pregnancy (HDPs) are common pregnancy complications and leading causes of pregnancy-related death in the United States. What is added by this report? During 2017–2019, HDP prevalence among delivery hospitalizations increased from 13.3% to 15.9%. The highest prevalence was among women aged 35–44 (18.0%) and 45–55 years (31.0%), and those who were Black women (20.9%) or American Indian and Alaska Native women (16.4%). Among deaths occurring during delivery hospitalization, 31.6% had a diagnosis code for HDP documented. What are the implications for public health practice? Severe HDP–associated complications and mortality are preventable with equitable implementation of quality improvement initiatives to recognize and promptly treat HDP and to increase awareness of urgent maternal warning signs.